Assessment of Cell-Free DNA with Microvascular Complication of Type II Diabetes Mellitus, Using PCR and Elisa

Tarhouny, Shereen A. El; Hadhoud, Khaled M.; Ebrahem, Magdy M; Azizi, Nashwa M Al

doi:10.1080/15257771003708298

Cited by 16 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CfDNA is higher in diabetic patients with and without microvascular complications in comparison to controls (Ref. 100) and in various acute disorders such as sepsis and respiratory failure (Refs 101, 102). Unsurprisingly, a recent study showed that cfDNA and nucleosomes are higher also in patients with haemolytic uremic syndrome very likely because of the activation of neutrophils (Ref.…”

Section: Sources Of Cfdna and Cfdna As A Biomarkermentioning

confidence: 99%

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

Celec

Vlková

Lauková

et al. 2018

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue -tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases.

show abstract

Section: Sources Of Cfdna and Cfdna As A Biomarkermentioning

confidence: 99%

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

Celec

Vlková

Lauková

et al. 2018

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

show abstract

“…cfDNA is derived from cell necrosis, apoptosis, and autonomic release following cellular synthesis of nucleic acids 2. Serum cfDNA levels were found to be elevated in patients with diabetes, and among patients with diabetes serum cfDNA levels were higher in patients with retinopathy than those without retinopathy 3. In addition, the elevation of cfDNA in patients with diabetes with DKD was more pronounced as compared with patients without DKD4…”

Section: Introductionmentioning

confidence: 99%

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Luo

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

AimsCell-free DNA (cfDNA) is associated with diabetes and cardiovascular diseases. Our study was to evaluate whether serum cfDNA could predict the progression of diabetic kidney disease (DKD).MethodsIn this prospective study, a total of 160 patients with DKD were enrolled, and the kidney function was followed up by measurement of estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) for three consecutive years. At baseline, concentrations of serum cfDNA were measured. DKD progression was defined as two-continuous decrease in eGFR and changes of UACR from less than 300 mg/g at baseline to higher than 300 mg/g at last follow-up. Regression models were used to analyze associations of serum cfDNA with the DKD progression.ResultsIn total, 131 patients finished all the follow-up visits. At the end of the study, 64 patients showed decreased eGFR and 29 patients had changes of UACR from less than 300 mg/g at baseline to higher than 300 mg/g at follow-up. At baseline, the progression group had higher serum cfDNA levels than the non-progression group (960.49 (816.53, 1073.65) ng/mL vs 824.51 (701.34, 987.06) ng/mL, p=0.014). Serum cfDNA levels were significantly negatively associated with the 1.5-year eGFR change (r=−0.219 p=0.009) and 3-year eGFR change (r=−0.181, p=0.043). Multivariate logistic analyses showed that after adjustment of age, gender, body mass index, fast plasma glucose, smoking, triglycerides, total cholesterol, duration of diabetes, systolic blood pressure, diabetic retinopathy, eGFR, high sensitivity C-reactive protein, angiotensin receptor blocker/ACE inhibitor usage, with the increase of one SD of serum cfDNA levels, the risk of DKD progression increased by 2.4 times (OR, 2.46; 95% CI 1.84 to 4.89).ConclusionSerum cfDNA is closely associated with DKD, and it might be a predictor of DKD progression in patients with type 2 diabetes.

show abstract

“…El Tarhouny et al [16] have reported that high levels of cfDNA were present not only in the complicated group but also in the diabetic patients without complications, although to a lesser extent. Tovbin et al [13] have found that cfDNA levels correlate with IL-6 and are particularly elevated in patients with proinflammatory conditions, such as DM.…”

Section: Discussionmentioning

confidence: 97%

Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients

Jeong

Moon

Choi

et al. 2015

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

BackgroundThe plasma levels of cell-free DNA (cfDNA) are known to be elevated under inflammatory or apoptotic conditions. Increased cfDNA levels have been reported in hemodialysis (HD) patients. The aim of this study was to investigate the clinical significance of cfDNA in HD patients.MethodsA total of 95 patients on HD were enrolled. We measured their predialysis cfDNA levels using real-time EIF2C1 gene sequence amplification and analyzed its association with certain clinical parameters.ResultsThe mean plasma cfDNA level in the HD patients was 3,884 ± 407 GE/mL, and the mean plasma cfDNA level in the control group was 1,420 ± 121 GE/mL (P < 0.05). Diabetic patients showed higher plasma cfDNA levels compared with nondiabetic patients (P < 0.01). Patients with cardiovascular complications also showed higher plasma cfDNA levels compared with those without cardiovascular complication (P < 0.05). In univariable analysis, the cfDNA level was associated with 3-month mean systolic blood pressure (SBP), white blood cell, serum albumin, creatinine (Cr), normalized protein catabolic rate in HD patients. In diabetic patients, it was significantly correlated with SBP, hemoglobin A1c, and serum albumin. In multivariate analysis, SBP was the independent determinant for the cfDNA level. In diabetic patients, cfDNA level was independently associated with hemoglobin A1c and SBP.ConclusionsIn patients with HD, cfDNA is elevated in diabetic patients and patients with cardiovascular diseases. Uncontrolled hypertension and poor glycemic control are independent determinants for the elevated cfDNA. Our data suggest that cfDNA might be a marker of vascular injury rather than proinflammatory condition in HD patients.

show abstract

Assessment of Cell-Free DNA with Microvascular Complication of Type II Diabetes Mellitus, Using PCR and Elisa

Cited by 16 publications

References 24 publications

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

Serum cell-free DNA and progression of diabetic kidney disease: a prospective study

Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients

Contact Info

Product

Resources

About